As of Nov 25
| -0.32 / -0.28%|
The 16 analysts offering 12-month price forecasts for Celgene have a median target of 148.50, with a high estimate of 163.00 and a low estimate of 97.00. The median estimate represents a +32.18% increase from the last price of 112.35.
The current consensus among 19 polled investment analysts is to Buy stock in Celgene. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.